Abstract 2328P
Background
A subset of cancers display distinctive phenotypes and harbor pathognomonic genetic alterations. Breast invasive lobular carcinoma (ILC), the most common special histologic subtype of breast cancer (BC), has a distinctive discohesive phenotype, caused by bi-allelic inactivation of CDH1 (E-cadherin), representing a strong genotypic-phenotypic correlation. Here, we sought to apply an artificial intelligence (AI)-based model trained to detect CDH1 bi-allelic mutations (i.e. inactivating mutation and loss of heterozygosity (LOH)) using H&E-stained whole slides images (WSI) as input to identify ILCs with alternative mechanisms of CDH1 inactivation.
Methods
We applied the AI-model trained to detect CDH1 biallelic mutations using WSIs to a cohort of 1,057 BCs with available targeted sequencing data. To determine the molecular underpinning of cases predicted to harbor CDH1 bi-allelic mutations but lacking these genetic alterations by targeted sequencing, we conducted the re-analysis of targeted sequencing data, CDH1 gene promoter methylation assessment and/or whole genome sequencing (WGS) analysis.
Results
We identified 34 cases predicted by the AI-model to harbor a CDH1 bi-allelic mutations that lacked these alterations by targeted sequencing. Reanalysis of targeted sequencing data and/or promoter methylation assessment revealed CDH1 promoter methylation (n=20), CDH1 homozygous deletions (n=3) and CDH1 intragenic deletion associated with LOH (n=1) in these cases. In addition, WGS of an ILC revealed a translocation t(13;16) predicted to result in a novel deleterious fusion gene affecting CDH1 with loss of exons 1-2 and the regulatory regions of this gene, associated with LOH. By applying a genomics-driven AI model we detected alternative mechanisms of CDH1 inactivation in 25/34 (74%) cases.
Conclusions
In the context of genotypic-phenotypic correlations, AI-based methods trained on a genetic ground truth can result in the identification of alternative/convergent molecular mechanisms underpinning histologic entities. This study highlights the potential of combinatorial approaches integrating deep learning methods and genomics in pathology.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Breast Cancer Research Foundation, National Institutes of Health (NIH)/National Cancer Institute.
Disclosure
Y.K. Wang, J. Bernhard, J. Sue, M.C.H. Lee, R. Godrich, A. Casson, J.D. Kunz, B. Rothrock, G.J. Oakley, D. Klimstra, T. Fuchs: Financial Interests, Personal, Stocks/Shares: Paige; Financial Interests, Personal, Full or part-time Employment: Paige. B. Weigelt: Financial Interests, Personal, Research Funding: Repare Therapeutics. C. Kanan: Financial Interests, Personal, Stocks/Shares, Also Consultant: Paige. J.S. Reis-Filho: Financial Interests, Personal, Other, Consultant: Goldman Sachs, Eli Lilly, Saga Diagnostics; Financial Interests, Personal, Other, Member of the Scientific Advisory Board and Consultant: Repare Therapeutics, Paige.AI; Financial Interests, Personal, Advisory Board: Personalis, Roche Tissue Diagnostics; Financial Interests, Personal, Advisory Board, Member of the Scientific Advisory Board: Bain Capital; Financial Interests, Personal, Advisory Board, Ad hoc member of the Pathology Scientific Advisory Board: Daiichi Sankyo, Merck; Financial Interests, Personal, Advisory Board, Ad hoc member of the Oncology Scientific Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board, Member of the SAB: MultiplexDX; Financial Interests, Personal, Member of Board of Directors: Odyssey Bio, Grupo Oncoclinicas; Financial Interests, Personal, Stocks/Shares: Repare Therapeutics; Financial Interests, Personal, Other, Stock options: Paige.AI. All other authors have declared no conflicts of interest.
Resources from the same session
2222P - Frequent TERT gains in metastatic papillary thyroid carcinoma
Presenter: Sara Gil
Session: Poster session 16
2223P - Next-generation sequencing enables identification of RET rearrangements in papillary thyroid cancer
Presenter: Sergi Clavé
Session: Poster session 16
2224P - Identifying prognostic factors in patients with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) treated with tyrosine kinase inhibitors (TKI): Data from REGETNE registry
Presenter: Maria Victoria San Roman Gil
Session: Poster session 16
2225P - FOX1 (rs965513), NKX2-1 (rs944289) and BRAF (V600E) gene mutations and their role in development of papillary thyroid cancer
Presenter: Darko Katalinic
Session: Poster session 16
2226P - Survival benefit of radioiodine therapy (RAI) in papillary thyroid cancer variants (PTCV): A SEER analysis
Presenter: Sakhr Alshwayyat
Session: Poster session 16
2227P - The efficacy and safety of lenvatinib in neoadjuvant therapy in patients with locally advanced thyroid cancer: A single-arm phase II clinical trial
Presenter: Jianhong Yu
Session: Poster session 16
2228P - Long-term clinical outcomes of Lenvatinib in patients with differentiated thyroid cancer: Results from the real-world practice of a single institution
Presenter: Ryutaro Onaga
Session: Poster session 16
2229P - Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001
Presenter: Lori Wirth
Session: Poster session 16
2323P - Multi-omic spatial phenotyping of the NSCLC tumour microenvironment for the development of a spatial score associated with immunotherapy resistance
Presenter: Arutha Kulasinghe
Session: Poster session 16
2324P - Trametinib and PD-1 combined blockade impairs tumor growth and improves survival of KRAS-mutant lung cancer through Id1 downregulation
Presenter: Ander Puyalto
Session: Poster session 16